자간전증 진단 시장 규모, 점유율, 성장 분석 : 검사 유형별, 제품별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Preeclampsia Diagnostics Market size was valued at USD 1.12 Billion in 2024 and is poised to grow from USD 1.15 Billion in 2025 to USD 1.47 Billion by 2033, growing at a CAGR of 3.1% during the forecast period (2026-2033).

The global market for preeclampsia diagnostics is experiencing significant growth driven by heightened awareness of maternal health and pregnancy complications. Preeclampsia, a hypertensive disorder impacting obstetrics, has spurred demand for precise and early diagnostic techniques, encouraging key players to innovate in this space. Factors such as increasing healthcare spending, enhancements in healthcare infrastructure in emerging markets, and the adoption of advanced medical technologies in obstetric care further bolster market expansion. Nonetheless, challenges like the high costs of sophisticated diagnostic methods and limited access to quality healthcare in specific regions could impede progress. Ongoing research into novel biomarkers and non-invasive diagnostic strategies is poised to propel the preeclampsia diagnostics market toward further advancements.

Top-down and bottom-up approaches were used to estimate and validate the size of the Preeclampsia Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Preeclampsia Diagnostics Market Segments Analysis

Global Preeclampsia Diagnostics Market is segmented by Test Type, Product, End-user and region. Based on Test Type, the market is segmented into Blood Tests, Urine Analysis and Others. Based on Product, the market is segmented into Instruments and Consumables. Based on End-user, the market is segmented into Hospitals, Specialty Clinics, Diagnostic Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Preeclampsia Diagnostics Market

The preeclampsia diagnostics market is driven by the complexities involved in accurately diagnosing this condition in expectant mothers. A mere spike in blood pressure does not provide a definitive diagnosis, which makes awareness crucial. Unfortunately, many women remain uninformed about preeclampsia and its associated risks, leading to a delay in recognizing hypertension during pregnancy. As symptoms often go unnoticed until they escalate, this gap in understanding limits the potential for timely intervention. The resulting health risks for mothers and their newborns can have severe consequences, contributing to higher rates of infant mortality and underscoring the urgent need for improved diagnostic solutions.

Restraints in the Preeclampsia Diagnostics Market

The preeclampsia diagnostics market faces significant challenges due to the complexity of accurately diagnosing this condition in pregnant women, as a mere rise in blood pressure does not provide definitive results. Additionally, a substantial number of pregnant individuals lack awareness about preeclampsia, its implications, and associated risks. Often, hypertension during pregnancy remains undetected until more severe symptoms develop, which restricts timely intervention opportunities. This gap in knowledge regarding the signs and potential complications of preeclampsia not only poses serious health risks to mothers but also increases the likelihood of higher infant mortality rates, presenting a critical barrier to market growth.

Market Trends of the Preeclampsia Diagnostics Market

The global preeclampsia diagnostics market is witnessing a noteworthy trend characterized by an enhanced focus on early risk assessment for expectant mothers. This shift is propelling the adoption of biomarker-based testing methods, which harness specific biological markers linked to preeclampsia. By facilitating the timely identification of potential cases, these tests empower healthcare professionals to administer early interventions and improve management strategies, ultimately fostering better outcomes for both mothers and their babies. As healthcare systems increasingly prioritize maternal health and preventative care, the integration of advanced diagnostic tools reflects a commitment to minimizing the adverse effects of preeclampsia on pregnancy outcomes.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Preeclampsia Diagnostics Market Size by Test Type & CAGR (2026-2033)

• Market Overview
• Blood Tests
• Urine Analysis
• Others

Global Preeclampsia Diagnostics Market Size by Product & CAGR (2026-2033)

• Market Overview
• Instruments
• Consumables

Global Preeclampsia Diagnostics Market Size by End-user & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Diagnostic Centers
• Others

Global Preeclampsia Diagnostics Market Size & CAGR (2026-2033)

• North America (Test Type, Product, End-user)
  • US
  • Canada
• Europe (Test Type, Product, End-user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Test Type, Product, End-user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Test Type, Product, End-user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Test Type, Product, End-user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Diabetomics Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DRG Instruments GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acon Laboratories, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arkray, Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cardinal Health (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (Beckman Coulter, Inc.) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DIRUI Industrial Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Metabolomic Diagnostics Ltd. (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sera Prognostics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Synlab Group (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Microlife Corporation (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Progenity Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations